Duodenal ischemia and upper GI bleeding are dose-limiting toxicities of 24-h continuous intra-arterial pancreatic perfusion of gemcitabine following vascular isolation of the pancreatic head: early results from the Regional Chemotherapy in Locally Advanced Pancreatic Cancer (RECLAP) study

[1]  D. Gouma,et al.  Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). , 2014, Surgery.

[2]  A. Krasinskas,et al.  Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer , 2013, Journal of surgical oncology.

[3]  He Ren,et al.  Regional Intra-Arterial vs. Systemic Chemotherapy for Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2012, PloS one.

[4]  S. Steinberg,et al.  Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial , 2011, Trials.

[5]  B. Erickson,et al.  Borderline Resectable Pancreatic Cancer: Definitions and the Importance of Multimodality Therapy , 2010, Annals of Surgical Oncology.

[6]  Chronic Disease Division.  Cancer facts and figures , 2010 .

[7]  Jeffrey E. Lee,et al.  Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Schellens,et al.  Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. , 2008, The oncologist.

[9]  Yao-ting Chen,et al.  A clinical study on continuous transarterial infusion chemotherapy and systemic venous chemotherapy with gemcitabine and 5-fluorouracil in treating patients with advanced pancreatic carcinoma , 2007 .

[10]  K. Aigner,et al.  Celiac axis infusion and microembolization for advanced stage III/IV pancreatic cancer--a phase II study on 265 cases. , 2005, Anticancer research.

[11]  G. Rosner,et al.  Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. Estey,et al.  Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[14]  T. Kusakabe,et al.  A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization , 2000, Cancer.

[15]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[16]  D. Winchester,et al.  Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. , 1999, Journal of the American College of Surgeons.

[17]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H. Hansen,et al.  A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. , 1996, British Journal of Cancer.

[19]  J. Chmiel,et al.  National patterns of care for pancreatic cancer. Results of a survey by the Commission on Cancer. , 1996, Annals of surgery.

[20]  J. Niederhuber,et al.  The national cancer data base report on pancreatic cancer , 1995, Cancer.

[21]  L. Hertel,et al.  Action of 2',2'-difluorodeoxycytidine on DNA synthesis. , 1991, Cancer research.

[22]  L. Hertel,et al.  Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). , 1990, Cancer research.

[23]  Richard G. Posner,et al.  Desmoplasia and chemoresistance in pancreatic cancer , 2012 .

[24]  H. Munshi,et al.  Pancreatic Cancer and Tumor Microenvironment , 2012 .

[25]  A. Bikhazi,et al.  Comparative Pharmacokinetics and Metabolic Pathway of Gemcitabine During Intravenous and Intra-arterial Delivery in Unresectable Pancreatic Cancer Patients , 2005, Clinical pharmacokinetics.

[26]  A. Ceribelli,et al.  Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels , 2004, Investigational New Drugs.

[27]  Xi Chen,et al.  Peripancreatic artery ligation and artery infusion chemotherapy for advanced pancreatic carcinoma. , 2003, Chinese medical journal.

[28]  J. Hainsworth,et al.  Randomized P hase I I C omparison o f D ose-Intense Gemcitabine: T hirty-Minute I nfusion a nd F ixed D ose R ate Infusion i n P atients W ith P ancreatic A denocarcinoma , 2003 .

[29]  A. Burroughs,et al.  Special article Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference , 2001 .

[30]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[31]  L. Brandt,et al.  Duodenal infarction after therapeutic gelfoam embolization of a bleeding duodenal ulcer , 1981 .